多格列艾汀治疗2型糖尿病的研究进展
Research Progress on Dorzagliatin in the Treatment of Type 2 Diabetes Mellitus
DOI: 10.12677/acm.2026.163938, PDF,    科研立项经费支持
作者: 寸淑华, 马晓玲, 范金成, 王 桔, 翁稚颖*：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明
关键词: 2型糖尿病；多格列艾汀；葡萄糖激酶激活剂；Type 2 Diabetes Mellitus； Dorzagliatin； Glucokinase Activator
摘要: 近年来，2型糖尿病(type 2 diabetes mellitus, T2DM)的治疗策略不断丰富，以葡萄糖激酶激活剂(glucokinase Activator, GKA)为代表的新型机制药物为血糖稳态调控提供了新思路。多格列艾汀作为全球首个获批上市的双重GKA，可同步作用于胰腺与肝脏的葡萄糖激酶，基于其关键Ⅲ期临床试验证据，该药目前已被推荐用于治疗成人T2DM，可单独使用或与二甲双胍联合应用。在疗效方面，多格列艾汀能有效降低血糖水平，并在改善血糖波动、保护β细胞功能方面显示出潜在优势。其安全性总体良好，常见不良反应发生率较低。未来研究方向包括探索其长期心血管安全性、在更广泛人群中的应用价值、以及与其他药物联用的优化方案。本文对多格列艾汀的作用机制、药代动力学特征、临床研究进展进行综述。
Abstract: In recent years, treatment strategies for type 2 diabetes mellitus (T2DM) have been continuously enriched. Novel mechanism-based agents, exemplified by glucokinase activators (GKAs), offer a new approach to modulating glucose homeostasis. Dorzagliatin, as the first globally approved dual-acting GKA, acts simultaneously on pancreatic and hepatic glucokinase, thereby restoring glucose-sensing function and early-phase insulin secretion impairment in T2DM patients. Supported by evidence from its pivotal phase III clinical trials, this agent is currently recommended for the treatment of adult T2DM, either as monotherapy or in combination with metformin. Regarding efficacy, dorzagliatin effectively lowers blood glucose levels and has shown potential advantages in improving glycemic variability and preserving β-cell function. Its safety profile is generally favorable, with a low incidence of commonly reported adverse events. Future research directions include evaluating its long-term cardiovascular safety, exploring its value in broader patient populations, and optimizing combination regimens with other anti-diabetic agents. This article provides a comprehensive review of the mechanism of action, pharmacokinetic properties, and clinical research progress of dorzagliatin.
文章引用：寸淑华, 马晓玲, 范金成, 王桔, 翁稚颖. 多格列艾汀治疗2型糖尿病的研究进展[J]. 临床医学进展, 2026, 16(3): 1556-1562. https://doi.org/10.12677/acm.2026.163938

参考文献

[1] 中华医学会糖尿病学分会, 等. 国家基层糖尿病防治管理指南2022 [J]. 中华内科杂志, 2022, 3(61): 249-262.
[2] Jiang, H., Zhou, X.E., Shi, J., Zhou, Z., Zhao, G., Zhang, X., et al. (2020) Identification and Structural Insight of an Effective PPARγ Modulator with Improved Therapeutic Index for Anti-Diabetic Drug Discovery. Chemical Science, 11, 2260-2268. [Google Scholar] [CrossRef] [PubMed]
[3] den Biggelaar, L.J.C.J., Sep, S.J.S., Eussen, S.J.P.M., Mari, A., Ferrannini, E., van Greevenbroek, M.M.J., et al. (2016) Discriminatory Ability of Simple OGTT-Based Beta Cell Function Indices for Prediction of Prediabetes and Type 2 Diabetes: The Codam Study. Diabetologia, 60, 432-441. [Google Scholar] [CrossRef] [PubMed]
[4] 中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 2型糖尿病基层合理用药指南[J]. 中华全科医师杂志, 2021, 20(6): 615-630.
[5] Derosa, G. and Maffioli, P. (2012) α-Glucosidase Inhibitors and Their Use in Clinical Practice. Archives of Medical Science, 8, 899-906. [Google Scholar] [CrossRef] [PubMed]
[6] Wei, Z., Weng, Y. and Zhang, Y. (2022) Investigation of the Repairing Effect and Mechanism of Oral Degraded Sericin on Liver Injury in Type II Diabetic Rats. Biomolecules, 12, Article 444. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, W., Yao, C., Shang, Q., Liu, Y., Liu, C. and Meng, F. (2020) Insights into the Binding of Dorzagliatin with Glucokinase: A Molecular Dynamics Simulation. Journal of Theoretical and Computational Chemistry, 19, Article 2050027. [Google Scholar] [CrossRef] 
[8] 赵紫楠, 史琛, 胡欣, 等. 葡萄糖激酶激活剂多格列艾汀药学专家共识[J]. 中国医院药学杂志, 2024, 44(3): 245-250.
[9] Matschinsky, F.M. (2009) Assessing the Potential of Glucokinase Activators in Diabetes Therapy. Nature Reviews Drug Discovery, 8, 399-416. [Google Scholar] [CrossRef] [PubMed]
[10] Matschinsky, F.M. (2013) GKAs for Diabetes Therapy: Why No Clinically Useful Drug after Two Decades of Trying? Trends in Pharmacological Sciences, 34, 90-99. [Google Scholar] [CrossRef] [PubMed]
[11] 栗玉杰, 张文静, 杨宏昕, 等. 多格列艾汀治疗2型糖尿病的快速卫生技术评估[J]. 药物流行病学杂志, 2025, 34(4): 448-455.
[12] 杜小雨, 李宇蒙, 吴惠珍, 等. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[13] Zhu, D., Zhao, Y., Tang, C., Tianxin, H., Li, Y., Zhao, G., et al. (2018) Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator Dorzagliatin (HMS5552)—Twelve Weeks Treatment in T2D Patients in China. Diabetes, 67, 1201-P. [Google Scholar] [CrossRef] 
[14] Ren, Y., Li, L., Wan, L., Huang, Y. and Cao, S. (2022) Glucokinase as an Emerging Anti-Diabetes Target and Recent Progress in the Development of Its Agonists. Journal of Enzyme Inhibition and Medicinal Chemistry, 37, 606-615. [Google Scholar] [CrossRef] [PubMed]
[15] Sanyoura, M., Letourneau, L., Knight Johnson, A.E., del Gaudio, D., Greeley, S.A.W., Philipson, L.H., et al. (2019) GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 Unpublished Variants. Diabetes Research and Clinical Practice, 151, 231-236. [Google Scholar] [CrossRef] [PubMed]
[16] Toulis, K.A., Nirantharakumar, K., Pourzitaki, C., Barnett, A.H. and Tahrani, A.A. (2020) Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. Drugs, 80, 467-475. [Google Scholar] [CrossRef] [PubMed]
[17] Rohli, K.E., Boyer, C.K., Blom, S.E. and Stephens, S.B. (2022) Nutrient Regulation of Pancreatic Islet β-Cell Secretory Capacity and Insulin Production. Biomolecules, 12, Article 335. [Google Scholar] [CrossRef] [PubMed]
[18] Moede, T., Leibiger, B., Vaca Sanchez, P., Daré, E., Köhler, M., Muhandiramlage, T.P., et al. (2020) Glucokinase Intrinsically Regulates Glucose Sensing and Glucagon Secretion in Pancreatic Alpha Cells. Scientific Reports, 10, Article No. 20145. [Google Scholar] [CrossRef] [PubMed]
[19] von Wilamowitz-Moellendorff, A., Hunter, R.W., García-Rocha, M., Kang, L., López-Soldado, I., Lantier, L., et al. (2013) Glucose-6-Phosphate-Mediated Activation of Liver Glycogen Synthase Plays a Key Role in Hepatic Glycogen Synthesis. Diabetes, 62, 4070-4082. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, K., Feng, L., Zhang, J., Zou, Q., Xu, F., Sun, Z., et al. (2023) Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus. Clinical Pharmacokinetics, 62, 1413-1425. [Google Scholar] [CrossRef] [PubMed]
[21] Sheng, L., Xu, H., Chen, W., Yuan, F., Yang, M., Li, H., et al. (2016) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Novel Glucokinase Activator HMS5552: Results from a First-in-Human Single Ascending Dose Study. Drug Design, Development and Therapy, 10, 1619-1626. [Google Scholar] [CrossRef] [PubMed]
[22] Zhu, D.L., Ding, Y.H., Xiao, D.W., et al. (2015) Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24 Hour Glucose and Improvement of β Cell Function in T2DM Patients.
https://www.huamedicine.com/publications-9
[23] Miao, J., Fu, P., Ren, S., Hu, C., Wang, Y., Jiao, C., et al. (2021) Effect of Renal Impairment on the Pharmacokinetics and Safety of Dorzagliatin, a Novel Dual‐Acting Glucokinase Activator. Clinical and Translational Science, 15, 548-557. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, F., An, B., An, W., Fu, G., Huang, W. and Yan, H. (2025) Application of Dorzagliatin in Peritoneal Dialysis Patients with Type 2 Diabetes Mellitus: A Case Report. World Journal of Diabetes, 16, Article 99135. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, L., Zhang, J., Sun, Y., Zhao, Y., Liu, X., Fang, Z., et al. (2023) A Phase I Open-Label Clinical Trial to Study Drug-Drug Interactions of Dorzagliatin and Sitagliptin in Patients with Type 2 Diabetes and Obesity. Nature Communications, 14, Article No. 1405. [Google Scholar] [CrossRef] [PubMed]
[26] Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., et al. (2018) Dorzagliatin Monotherapy in Chinese Patients with Type 2 Diabetes: A Dose-Ranging, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. The Lancet Diabetes & Endocrinology, 6, 627-636. [Google Scholar] [CrossRef] [PubMed]
[27] Zhu, D., Li, X., Ma, J., Zeng, J., Gan, S., Dong, X., et al. (2022) Dorzagliatin in Drug-Naïve Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. Nature Medicine, 28, 965-973. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, Y., Su, X., Zhang, W., Zhou, Y., Zhou, X., Yang, W., et al. (2023) Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology, 2023, Article ID: 4996057. [Google Scholar] [CrossRef] [PubMed]
[29] Zeng, J., Gan, S., Mi, N., Liu, Y., Su, X., Zhang, W., et al. (2023) Diabetes Remission in Drug‐Naïve Patients with Type 2 Diabetes after Dorzagliatin Treatment: A Prospective Cohort Study. Diabetes, Obesity and Metabolism, 25, 2878-2887. [Google Scholar] [CrossRef] [PubMed]
[30] Yang, W., Zhu, D., Gan, S., et al. (2022) Dorzagliatin Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. Nature Medicine, 28, 974-981.
[31] 赖迎春. 多格列艾汀治疗二甲双胍单药控制不佳2型糖尿病的有效性与安全性随机对照研究[J]. 医师在线, 2026, 16(1): 52-55.
[32] 彭湾湾, 薛君力, 曾姣娥. 多格列艾汀联合二甲双胍治疗初发超重/肥胖2型糖尿病患者的有效性及安全性研究[J]. 中国现代医生, 2024, 62(34): 63-67.
[33] 李爱, 许淑贞, 黎婕. 二甲双胍联用多格列艾汀治疗糖尿病的效果对比[J]. 糖尿病新世界, 2024, 27(24): 99-101+113.
[34] Davies, M.J., D’Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., et al. (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. a Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41, 2669-2701. [Google Scholar] [CrossRef] [PubMed]
[35] Perreault, L., Skyler, J.S. and Rosenstock, J. (2021) Novel Therapies with Precision Mechanisms for Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 17, 364-377. [Google Scholar] [CrossRef] [PubMed]

为你推荐